Barclays lowered the firm’s price target on CVS Health to $63 from $65 and keeps an Equal Weight rating on the shares post the Q2 report. The firm says that despite risk to 2025 Medicare Advantage bids, the company’s path to double-digit earnings growth still looks achievable.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVS:
- CVS Health says majority of businesses ‘performing well’
- CVS Earnings: CVS Health Earnings Shine but Outlook Dims
- Options Volatility and Implied Earnings Moves Today, August 07, 2024
- CVS HEALTH CORPORATION REPORTS SECOND QUARTER 2024 RESULTS AND REVISES FULL-YEAR 2024 GUIDANCE
- CVS Health cuts FY24 adjusted EPS view to $6.40-$6.65 from at least $7.00
Questions or Comments about the article? Write to editor@tipranks.com